Natural Capsules Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
NATCAPSUQ · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Natural Capsules Limited reported its Q1 FY26 results. On a standalone basis, revenue from operations grew about 13% year-on-year to Rs 4,424.29 lakhs (from Rs 3,913.59 lakhs), while net profit jumped roughly 73% to Rs 252.30 lakhs (from Rs 145.91 lakhs), pushing EPS to Rs 2.44 vs Rs 1.56. Total income, including other income, stood at Rs 4,593.37 lakhs. However, on a consolidated basis the company swung to a net loss of Rs 558.05 lakhs, compared to a profit of Rs 60.33 lakhs a year ago, mainly because its new subsidiary Natural Biogenex (API segment) only began commercial operations on March 31, 2025 and is incurring full expenses without matching revenue yet. The API segment posted a segment loss of Rs 698.55 lakhs. The auditor (P. Chandrasekar LLP) issued an unmodified limited review report on both sets of results.
Standalone numbers are strong, showing healthy revenue and profit growth, which is positive for shareholders. However, the consolidated loss is a red flag — investors should watch whether the new API subsidiary ramps up revenues in coming quarters, as continued losses at this scale could pressure the consolidated bottom line and weigh on the stock despite the solid standalone performance.